Alembic Pharma Q4 Review - Non-U.S. Markets, API Drive Earnings: Motilal Oswal
Tablets fall from a machine during production. (Photographer: Andrey Rudakov/Bloomberg)

Alembic Pharma Q4 Review - Non-U.S. Markets, API Drive Earnings: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Alembic Pharmaceuticals Ltd.’s Q4 FY21 operational performance was marginally below estimates, largely due to lower traction in U.S./domestic formulation sales.

The company awaits feedback from the U.S. food and drug administration on the resolution of observations at the recently inspected injectables unit (F3).

Revenues were up 6.1% YoY to Rs 12.8 billion (our estimate Rs 13.3 billion), led by 77% YoY growth in Non-U.S. export sales (Rs 2.3 billion; 18% of sales) and 38% YoY growth in active pharmaceutical ingredient sales (Rs 2.1 billion; 17% of sales).

We tweak our estimates for FY22/FY23, factoring in -

  1. a slowdown in U.S. sales and
  2. lower expensing of operational cost related to newer facilities.

Click on the attachment to read the full report:

Motilal Oswal Alembic Pharma Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.